.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A systematic review and meta-analysis evaluated allergen immunotherapy for asthma, bringing together evidence on clinical outcomes and treatment effects across different forms of immunotherapy. The overall evidence suggested potential benefit for selected patients, particularly when allergic sensitization is clearly demonstrated and treatment is delivered in an appropriate clinical context. The paper is useful because it also highlights the limits of a one-size-fits-all approach. Immunotherapy is not simply another add-on for uncontrolled asthma; candidacy depends on the patient’s allergic phenotype, disease stability, relevant allergen exposure, and the balance of expected benefit and treatment burden. For HCPs, the practical workflow is to confirm clinically relevant sensitization, optimize standard asthma therapy, address adherence and inhaler technique, and then consider immunotherapy in patients who fit established criteria. This evidence aligns with the conference workshop on allergy and immunotherapy and with its broader focus on asthma phenotyping in everyday practice. The key message is therefore one of precision and selection: immunotherapy can be valuable for the right patient, but the quality of the phenotype and the clinical indication matter as much as the intervention itself.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A systematic review and meta-analysis evaluated allergen immunotherapy for asthma, bringing together evidence on clinical outcomes and treatment effects across different forms of immunotherapy. The overall evidence suggested potential benefit for selected patients, particularly when allergic sensitization is clearly demonstrated and treatment is delivered in an appropriate clinical context. The paper is useful because it also highlights the limits of a one-size-fits-all approach. Immunotherapy is not simply another add-on for uncontrolled asthma; candidacy depends on the patient’s allergic phenotype, disease stability, relevant allergen exposure, and the balance of expected benefit and treatment burden. For HCPs, the practical workflow is to confirm clinically relevant sensitization, optimize standard asthma therapy, address adherence and inhaler technique, and then consider immunotherapy in patients who fit established criteria. This evidence aligns with the conference workshop on allergy and immunotherapy and with its broader focus on asthma phenotyping in everyday practice. The key message is therefore one of precision and selection: immunotherapy can be valuable for the right patient, but the quality of the phenotype and the clinical indication matter as much as the intervention itself.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
